MALTリンパ腫の分子および細胞学的特徴
解剖学的部位を横断したMALTリンパ腫の分子・細胞学的特徴:統合的トランスクリプトミクスおよびエピジェネティクスアプローチ
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites.
Using participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.
調査の概要
状態
状態
条件
条件
詳細な説明
Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' charts or electronic medical records upon receipt of ethical approval. Each patient enrolled in the study will be assigned a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data and to label biological samples. The coded biological material will be transferred to the coordinating center at the Institute of Oncology Research (IOR) in Bellinzona. Health-related data will be collected in the electronic case report form (eCRF) (OpenClinica). Data quality will be ensured by query generation.
Annotated baseline features will include the date of diagnosis, date of biopsy, age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Ann Arbor stage, lactate dehydrogenase (LDH), number and location of extranodal sites, bone marrow involvement and percentage, peripheral blood involvement, number of nodal sites, B symptoms, lymph nodes larger than 7 cm, hemoglobin (Hb), platelets, lymphocytes, beta-2-microglobulin, albumin, infections (hepatitis C virus, Helicobacter pylori, Chlamydophila psittaci, Achromobacter xylosoxidans, Campylobacter jejuni), serum paraprotein presence and type.
Annotated follow-up features included the date of progression to a disease requiring treatment, type of first-line treatment, date of start of the first line treatment, date of progression after first line treatment, date of the second line treatment, type of second line treatment, date of transformation, date of death, cause of death, and date of last follow-up. Mutation analysis, immunoglobulin genes and T cell receptor rearrangement analysis, copy number aberration analysis, structural variant analysis, and deoxyribonucleic acid (DNA) methylation profile will be performed by next-generation sequencing of genomic DNA extracted from the biopsy. Gene expression will be assessed by next-generation sequencing of RNA extracted from the biopsy. Protein expression will be assessed by mass spectrometry of proteins extracted from the biopsy. AI-based computational pathology will be performed on digitized whole-slide images of the biopsy to extract quantitative histologic features.
Single-cell transcriptomic profiling will be used to resolve intratumoral heterogeneity and to define malignant and non-malignant cellular populations. After quality control, normalization, and batch correction, unsupervised clustering will be applied to identify transcriptionally distinct cell states. Malignant B-cell populations will be distinguished from reactive B cells using a combination of copy number inference, immunoglobulin expression patterns, and canonical marker genes. Differential expression and pathway enrichment analyses will be conducted to identify signaling programs associated with anatomical site, immune context, and disease features.
In details:
- Spatial transcriptomics and/or spatial proteomics will be employed to preserve tissue architecture and assess the spatial organization of tumor cells, immune infiltrates, and stromal components. Spatial domains and cellular neighborhoods will be identified using data-driven segmentation and neighborhood analysis approaches. Spatial co-localization and interaction analyses will be used to infer tumor-microenvironment crosstalk, immune exclusion or activation niches, and site-specific spatial patterns that may influence therapeutic response.
- Immune repertoire profiling (BCR/TCR sequencing) will be integrated, where available, to assess clonality, antigen-driven selection, and spatial distribution of immune clones. In malignant B cells, immunoglobulin features will be used to explore evidence of antigen dependence and ongoing selection, while TCR diversity and expansion will be evaluated in relation to immune niches and tumor proximity.
- Proteomic and/or epigenetic data, when available, will be incorporated to refine functional interpretation of transcriptional programs and to identify post-transcriptional or regulatory mechanisms underlying observed cellular states.
Cross-modal integration will be performed using established computational frameworks to generate unified cell state annotations and pathway activity scores. Comparative analyses across anatomical sites will be a central assessment. Conserved versus site-specific cellular states, immune compositions, and signaling pathways will be systematically evaluated to identify shared disease mechanisms as well as context-dependent features. Associations with clinical variables (e.g., site of origin, prior treatment, disease stage) will be explored in an exploratory, hypothesis-generating manner.
All analyses will follow reproducible computational workflows with stringent quality control, appropriate correction for technical confounders, and transparent reporting of limitations. The resulting datasets and analytical outputs will provide an integrated molecular and spatial reference framework for MALT lymphoma, supporting downstream biomarker discovery and future translational studies.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:International Extranodal Lymphoma Study Group - IELSG
- 電話番号:+41 58 666 7321
- メール:ielsg@ior.usi.ch
研究場所
-
-
-
Milan、イタリア、20132
- IRCCS Ospedale San Raffaele
-
主任研究者:
- Maurilio Ponzoni, MD
-
コンタクト:
- Maurilio Ponzoni, MD
- メール:ponzoni.maurilio@hsr.it
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult patients with diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000
説明
Inclusion Criteria:
- Male or female adults 18 years or older
- Diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000.
- Availability of tumor material from biopsies (either frozen or formalin-fixed paraffin-embedded) (FFPE).
- Availability of the baseline and follow-up annotations.
Exclusion Criteria:
- None
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Molecular and spatial profiles of MALT lymphoma
時間枠:6 months: from the end of samples collection to the end of study analysis
|
Generation of high-resolution molecular and spatial profiles of MALT lymphoma tissues, including annotation of malignant and non-malignant cell populations. |
6 months: from the end of samples collection to the end of study analysis
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
組織切片から人工知能(AI)を用いて臨床的に重要な特徴を抽出する
時間枠:6か月: サンプル収集終了から研究分析終了まで
|
6か月: サンプル収集終了から研究分析終了まで
|
|
|
Creation of a curated multi-omics dataset
時間枠:6 months: from the end of samples collection to the end of study analysis
|
Identification of spatial tumor-immune interactions, characterization of BCR/TCR clonality, derivation of molecular signatures associated with anatomical site and microenvironment, and creation of a curated multi-omics dataset suitable for deposition in controlled-access repositories |
6 months: from the end of samples collection to the end of study analysis
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Luciano Cascione, PhD、Foundation for the Institute of Oncology Research
- スタディチェア:Francesco Bertoni, MD、Foundation for the Institute of Oncology Research
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IELSG56
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Processed molecular data, including single-cell and spatial transcriptomic matrices, cell type annotations, and derived pathway activity scores, will be made available to the scientific community through established public repositories (e.g. GEO, ArrayExpress, or Zenodo), such as controlled-access archives for human genomics data, once primary analyses and initial publications are completed.
IPD 共有時間枠
From March 2029 to March 2035
IPD 共有アクセス基準
Raw sequencing data will be deposited where permitted by consent and regulatory frameworks or otherwise shared in controlled-access form to qualified researchers upon reasonable request. Analysis code, computational workflows, and documentation will be shared via publicly accessible version-controlled repositories to ensure transparency and reproducibility
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。